Ipsen: Dysport® now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy
Accessed November 2019.Craven, B., Morris, A. Modified Ashworth scale reliability for measurement of lower extremity spasticity among patients with SCI. Spinal Cord 2010; 48: 207–213.Ipsen. Data on File.Hoare, J Child Neurol. 2014; 29(8):1066-76.The Hillingdon hospitals NHS Foundation Trust. Patient information leaflet. Spasticity and its management. Last accessed: November 2019.Physical effects of stroke. Stroke Association www.stroke.org.uk
. Last accessed: November 2019.Lynn Bar-On et al. Spasticity and its contribution to hypertonia in cerebral palsy. Biomed Res Int. 2015; 2015: 317047.Pirazzini, M., Rossetto, O., Eleopra, R. & Montecucco, C. Pharmacol. Rev. 200–235 (2017). doi:10.1124/pr.116.012658Santos CA, Franco de Moura RC, Lazzari RD, Dumont AJ, Braun LA, Oliveira CS. J Phys Ther Sci 2015; 27(5): 1617-20.Colver A, Fairhurst C, Pharoah PO. Cerebral palsy. Lancet 2014; 383(9924): 1240-9.SmPC Dysport 500 Units. 175.1_DYS500_UK.Erbguth FJ. J Nerual Transm 2007;115: 559-65.Jitpimolmard S, et al. J Neurol Neurosurg Psychiatry 1998;64(6):751-757.Ipsen. Neuroscience. Available from:https://www.ipsen.com/our-science/neuroscience/
. Accessed November 2019.Ipsen. Data on File. DYS-UK-003296. May 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200105005039/en/